Key Takeaways
- Private doctor-to-doctor sales often deliver 80–100% cash at close and a full exit in 30–90 days. DSO deals in 2026 commonly average about 65% cash with 3–5 year employment commitments.
- DSO headline valuations of 6–9× EBITDA can exceed private-sale multiples. The real after-tax outcome can depend on equity rollover, earnout performance, and overall deal structure.
- Staff and patient continuity tends to be more predictable in private transitions. DSO affiliations usually shift HR, benefits, and non-clinical operations to corporate systems immediately at close.
- Choosing a poorly positioned DSO can lock 20–40% of deal value in illiquid equity for 5–7 years. McLerran vets every buyer for financial strength and post-close seller satisfaction.
- McLerran & Associates runs a competitive, dual-path process that models real after-tax proceeds across 3-, 5-, and 7-year horizons. Connect with McLerran & Associates confidentially to see which path can better support your goals and protect your legacy.
Valuation, Cash at Close, and Work-Back Period Compared
The table below compares the two transition paths across five dimensions using 2026 market benchmarks. Each figure comes from current industry data and is explained in more detail in the sections that follow.
| Dimension | Private (Doctor-to-Doctor) Sale | DSO Affiliation |
|---|---|---|
| Headline Valuation | 60–85% of annual collections, or roughly 2.5–4.5× adjusted EBITDA for solo practices sold to individual buyers | 6–9× normalized EBITDA for practices with $500K–$3M EBITDA; higher for platform-level deals |
| Cash at Close | 80–100% of purchase price paid in cash at closing | Average 65% cash at close in 2026, with the balance in equity rollover and/or earnout |
| Work-Back Period | 30–90 days; seller exits completely after a brief patient-introduction period | 3–5 year employment agreement as a clinical associate at 25–35% of collections |
| Control / Autonomy | Seller exits; buyer assumes full operational control immediately after closing | Clinical autonomy generally preserved, while non-clinical operations transfer to the DSO at close |
| Staff & Patient Continuity | Continuity depends on buyer’s philosophy; private transitions can be more likely to preserve original team culture | Clinical staff typically retained; HR, benefits, and admin systems shift to DSO model |
Request a confidential side-by-side valuation from McLerran & Associates to see what your practice could be worth on both paths in 2026.
Example: How DSO Cash, Equity, and Earnout Work Together
Headline numbers in DSO offers can look impressive, yet the structure behind them can change the real outcome. Consider a realistic 2026 scenario for a general dentistry practice generating $1.5 million in annual collections with a 30% EBITDA margin. That margin produces $450,000 in normalized EBITDA, which means earnings before interest, taxes, depreciation, and amortization, adjusted for owner-specific expenses.
A qualified private buyer, financing through an SBA loan, might offer approximately $1.2 million, or roughly 80% of trailing collections, with 80–100% of that amount paid in cash at closing. The seller often walks away in 60–90 days with roughly $960,000–$1.2 million in hand.
A DSO, applying a 6–7× EBITDA multiple, might quote a headline of $2.7–$3.15 million. Using a 2026 structure with roughly 65% cash at close, that same offer delivers approximately $1.75–$2.05 million at closing. The remaining 35%, or roughly $945,000–$1.1 million, arrives as a combination of rollover equity and an earnout. The rollover equity is an ownership stake in the DSO that is typically illiquid for 5–7 years. The earnout is a performance-contingent payment measured over 12–36 months after closing.
Modeled across time horizons, the picture can shift materially:
- Year 3: The private-sale seller has been free for nearly three years and can invest or deploy their $1.2 million cash. The DSO seller has received cash at close plus some earnout payments, but the equity remains locked, and after-tax associate income has replaced owner distributions at a lower rate.
- Year 5: If the DSO performs well and recapitalizes, the equity stake can begin to generate a “second bite of the apple.” If the DSO underperforms, that equity may be worth less than projected or nothing at all.
- Year 7: A well-chosen DSO partner with strong private equity backing can produce total after-tax proceeds that exceed the private-sale outcome. A poorly chosen one can produce the opposite.
McLerran & Associates responds to this complexity with a CPA-led, multi-year cash-flow model for every client. The firm quantifies real after-tax proceeds across 3-, 5-, and 7-year horizons before any letter of intent is signed.
Ask McLerran & Associates to model your DSO and private-sale cash flows before you negotiate with any buyer.
Private Sale Work-Back Period and Lifestyle Impact
Post-close lifestyle can be one of the most consequential and least discussed differences between the two paths. In a doctor-to-doctor sale, the typical work-back period runs 30–90 days. During that window, the selling dentist introduces patients to the new owner, hands off clinical relationships, and trains the buyer on practice systems.
After that period, the seller usually exits completely. McLerran often structures these as “walk-away sales,” where the seller works back approximately 4–8 weeks and then is free to retire, relocate, or pursue other interests.
In a DSO affiliation, the post-close commitment usually looks categorically different. DSO acquisitions typically require a 3–5 year employment agreement, during which the selling dentist continues as a clinical associate. Compensation shifts from owner distributions to 25–35% of net collections, which can be meaningfully lower than prior owner income. Non-clinical decisions such as staffing, scheduling, equipment, and marketing transfer to the DSO immediately at close.
Non-compete agreements in dental practice sales commonly run 2–5 years in duration with geographic radius restrictions. The employment agreement’s terms, including minimum hours, exit rights, and clinical autonomy protections, can be as economically significant as the headline purchase price.
A 55-year-old owner who wants to be done in two years may find that a 5-year DSO employment agreement functions more like a new job than a transition. An owner who wants to keep practicing while taking chips off the table may find that same agreement fits their goals. Clarifying which scenario applies usually starts with an honest conversation about the seller’s reasons for selling before any path is chosen.
Talk with McLerran & Associates about your ideal transition timeline before you sign a DSO letter of intent.
How DSO EBITDA Multiples Compare to Collections Multiples
Private sales and DSO affiliations use different valuation languages, which can make direct comparison difficult without translation. Private buyers, usually individual dentists financing through SBA or conventional lending, are constrained by the practice’s post-sale cash flow after the buyer’s own income.
That constraint means private sales typically close at 60–85% of annual collections, or roughly 2.5–4.5× adjusted EBITDA for solo practices. This pattern reflects the economic reality of what an individual buyer can finance. It does not necessarily signal a weak process.
DSOs, backed by institutional capital, apply EBITDA multiples that individual buyers usually cannot match. Formal DSOs acquiring practices with $500K–$3M in EBITDA typically offer 6–9× normalized EBITDA in 2026. The higher end of that range often goes to multi-provider practices with strong hygiene revenue, scalable infrastructure, and lower key-person risk. Practices with $1–3M in EBITDA that fit a regional DSO’s add-on model can sometimes achieve 7–9× in 2026.
The critical variable that influences where a practice lands within those ranges is EBITDA itself. EBITDA does not appear on a tax return. It requires a CPA-led analysis that identifies and adds back every discretionary, personal, and non-recurring expense to arrive at true normalized profitability. A weak or incomplete add-back analysis produces a lower EBITDA, which anchors the multiple to a lower base and quietly determines what the owner walks away with.
McLerran & Associates builds diligence-grade EBITDA analyses up front, before the practice goes to market, so the number can hold when DSO buyers scrutinize it during due diligence and the deal is less likely to be re-traded downward at the last moment.
Contact McLerran & Associates for a confidential EBITDA and valuation review to see what multiple your practice might command in today’s market.
Staff and Patient Outcomes in Each Transition Path
Legacy protection often sits at the center of many owners’ decisions and can be one of the main factors in choosing the right buyer and path. In a private, doctor-to-doctor sale, continuity depends heavily on the incoming dentist’s clinical philosophy and management style.
Private transitions can be more likely to preserve the original team culture and treatment philosophy, particularly when the seller selects a buyer who shares their values. Dental practices with well-managed ownership transitions often retain 80–95% of patients in the first year. A structured 30–90 day introduction period can be a key driver of that retention.
In a DSO affiliation, clinical staff are typically retained to preserve operational continuity. Hygienists and assistants usually stay, while some administrative roles may change as the DSO implements its operating model. HR, benefits, and compensation systems transfer to the DSO’s corporate structure, which can mean improved benefits for staff along with a more corporate employment relationship. Many DSO transitions are designed to feel seamless from the patient perspective, with most patients learning of the change only after closing.
Verbal assurances from a DSO buyer about staff retention carry no legal weight. Sellers can protect their teams more effectively by negotiating explicit staff retention commitments in the asset purchase agreement rather than relying on promises made during early conversations.
McLerran & Associates focuses on both price and fit, working to find a buyer whose strategy, structure, and support model align with what the seller wants for their practice after they step away. That fit often represents half of the firm’s mandate on every engagement.
Start a confidential conversation with McLerran & Associates about how to protect your staff and patients on either transition path.
DSOs to Approach Carefully
Not all DSOs function as equal partners, and choosing the wrong one can have serious consequences. Rollover equity in DSO acquisitions is typically illiquid for 5–7 years. A seller who partners with an undercapitalized or poorly managed DSO may find that 20–40% of their total deal value is tied to an organization that later struggles or faces financial distress.
North American DSO deal activity slowed after 2022, and some buyers that entered the market when capital was cheap after COVID have since encountered operational and financial difficulties. The DSO landscape in 2026 includes well-backed, well-run organizations with strong track records of satisfied sellers. It also includes buyers that may not belong at a seller’s negotiating table.
McLerran & Associates vets every buyer in its pool like an investment. The firm evaluates:
- Whether the DSO’s overall portfolio is profitable and still growing at offices it already owns
- The strength and experience of the management team
- The track record and financial backing of the private equity firm behind the DSO
- Post-close seller satisfaction, sourced from dentists who have already affiliated with that buyer
DSOs known for creating poor post-close environments are removed from McLerran’s buyer pool. Examples include production quotas that compromise clinical autonomy, aggressive earnout structures that shift risk entirely to the seller, or cultural mismatches that drive staff turnover.
Reach out to McLerran & Associates to discuss which DSOs are vetted partners in 2026 and which ones may warrant caution.
How McLerran & Associates Creates Competition and Protects Sellers
A practice owner who approaches a single DSO directly often negotiates from a significant information disadvantage. That DSO structures deals every week, while the seller may do this once in a lifetime. The valuation anchor set in that first conversation can quietly determine what the owner walks away with.
McLerran & Associates levels that table through a structured, auction-like process that typically runs 45–60 days and generates approximately 10 offers per listing. The process works as follows:
- A CPA-led EBITDA analysis and comprehensive practice valuation is completed up front. This diligence-grade work controls the narrative around profitability before any buyer sees the numbers and becomes the foundation for all subsequent marketing materials.
- Using that valuation, a marketing deck and virtual data room are built, showcasing everything worth highlighting about the practice in a format that institutional buyers expect.
- With the data room ready, offers are solicited from a vetted pool of strategic buyers, such as DSOs integrating the practice into existing infrastructure, and financial buyers, such as family offices and private equity groups, including those seeking a platform acquisition.
- Approximately 10 initial offers are narrowed to the top one to three finalists through in-person meetings or headquarters visits.
- McLerran negotiates all aspects of the letter of intent on the seller’s behalf, including valuation, cash at close, equity structure, and earnout terms.
- After the LOI, McLerran provides “quality of earnings” defense through due diligence and reminds buyers that other vetted bidders are waiting if they attempt to re-trade the agreed value.
The numbers behind this approach include approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, more than 10,000 practices evaluated, and a transaction rate of approximately 85–90%. Industry norms often sit closer to 35–40%. Clients frequently achieve approximately 30% higher valuations than owners who sell on their own, and do-it-yourself close rates can run as low as 15–20% versus roughly 80% for a well-run brokered process.
McLerran works both the private-buyer and DSO pathways in roughly equal measure, a 50/50 split that single-lane brokers usually cannot replicate. That balance is what makes a genuine side-by-side comparison possible.
Start the process with McLerran & Associates to create real competition for your practice and compare DSO and private-sale outcomes on equal footing.
Frequently Asked Questions
Can I get a mostly-cash deal from a DSO?
Some sellers can secure mostly-cash DSO deals, and the likelihood depends heavily on market, practice profile, and active buyers. A high cash-at-close structure, often in the range of 70–75% or above, can be achievable for practices with strong EBITDA margins, low Medicaid exposure, and multiple providers. It tends to be harder in markets where DSO buyers favor heavier equity rollover requirements.
McLerran tracks which buyers in each geography are currently offering cash-heavy structures and can target those buyers specifically during the competitive bid process. A vetted pool of buyers, rather than a single DSO, allows sellers to compare cash-at-close terms across multiple offers instead of accepting whatever one buyer proposes.
Do I have to keep working after I sell?
The answer usually depends on the chosen path. In a private, doctor-to-doctor walk-away sale, the typical work-back period is approximately 4–8 weeks. That window allows time to introduce patients to the new owner and hand off clinical relationships, after which the seller exits completely.
In a DSO affiliation, a multi-year employment agreement is standard. A minimum of three years is common, and five-year agreements are not unusual, particularly when a significant portion of practice revenue is tied to the selling dentist’s patient relationships. A shorter work-back may be negotiable if the seller has already reduced chair time and associate production is strong.
McLerran negotiates employment agreement terms, including minimum schedule, exit rights, and clinical autonomy protections, as part of every DSO engagement. Those terms can be as economically significant as the headline purchase price.
How do I know if a DSO offer is actually good?
The headline number often provides the least reliable signal of whether a DSO offer is strong. A more complete view looks at cash-at-close percentage, earnout terms, rollover equity quality, and employment agreement conditions.
A strong offer can feature competitive cash at close, non-punitive earnout terms such as pro-rata provisions that pay a proportional amount even if a target is narrowly missed, and rollover equity in a well-capitalized organization with a credible path to a future recapitalization. The employment agreement should preserve clinical autonomy without imposing production quotas that compromise patient care.
McLerran builds a multi-year, multi-structure financial model for every finalist offer, quantifying real after-tax proceeds across 3-, 5-, and 7-year horizons. That modeling, combined with the firm’s buyer-vetting process, can help distinguish a genuinely strong offer from one that only looks attractive on the surface.
What happens to my staff if I sell to a DSO versus a private buyer?
In a DSO affiliation, clinical staff such as hygienists, assistants, and front-desk team members are typically retained to preserve operational continuity. HR systems, benefits structures, and compensation models shift to the DSO’s corporate framework, which changes the employment relationship even when the faces in the office stay the same. Administrative roles may be consolidated as the DSO implements its operating model.
In a private, doctor-to-doctor sale, staff continuity depends primarily on the incoming dentist’s management philosophy and whether they share the seller’s values. Private transitions tend to preserve original team culture more reliably when the seller selects a buyer with a compatible clinical and operational approach.
In either case, verbal assurances from a buyer about staff retention carry no legal weight. Those commitments belong in the asset purchase agreement. McLerran negotiates explicit staff retention provisions as a standard part of every engagement, because protecting the team can be a key part of protecting the practice’s legacy.
Conclusion: Choose the Path That Fits Your Goals
The DSO vs. private sale decision rarely has a universal right answer. It usually has a right answer for your practice, your timeline, your financial goals, and the legacy you want to leave. A private sale can deliver a clean, mostly-cash exit in weeks. A DSO affiliation can deliver a larger total outcome over years if the buyer is well chosen, the structure is negotiated carefully, and after-tax modeling is completed before the letter of intent is signed.
A meaningful comparison often requires an advisor who works both paths in equal measure, builds diligence-grade valuations that hold up under scrutiny, creates real competition among a vetted buyer pool, and models the true economic outcome across time horizons rather than focusing only on the headline number on a term sheet.
That approach reflects what McLerran & Associates provides. The firm’s track record has been built over nearly 35 years, supported by a team carrying over 100 years of collective dental-industry experience, and a history of guiding dentists through both pathways in roughly equal measure so every client can see the full picture before choosing.
Contact McLerran & Associates for a confidential side-by-side valuation and multi-year cash-flow model to clarify which path, DSO affiliation or private sale, can better support your goals in 2026. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us.
